Generic ticagrelor?

Short answer: generic ticagrelor exists in some markets, but availability varies by country and regulatory status.

What this means for you
- In the United States: as of 2024, Brilinta (ticagrelor) is the branded product and a widely available generic may not be on the US market yet. Availability can depend on patent expiry and payer approval.
- Elsewhere (EU, Canada, other countries): generics have been launched in some places after patent protection ended.

How to check the status for you
- If you’re in the US: check the FDA’s Orange Book for ticagrelor (ticagrelor API and brand/tables) to see if a generic has been approved and by whom.
- If you’re outside the US: check your national medicines regulator or pharmacist for the latest generic ticagrelor availability.
- You can also ask your pharmacist or insurer about price and formulary coverage, and whether a generic version is expected soon.

What to know about ticagrelor (brief)
- Use: antiplatelet therapy to reduce risk of stroke, heart attack, and death in certain acute coronary syndrome settings; usually with low-dose aspirin.
- Dosing (typical): 180 mg loading dose, then 90 mg twice daily, with low-dose aspirin (often 81 mg daily).
- Important: do not use high-dose aspirin with ticagrelor; monitor for bleeding and dyspnea; consult a clinician before switching formulations.

If you tell me your country (or region), I can give a more targeted update on current generic status and any cost considerations.